Fly News Breaks for August 27, 2019
Aug 27, 2019 | 16:20 EDT
Stifel analyst Mathew Blackman started Cerus with a Buy rating and $7 price target. The analyst sees "significant potential upside" over time as the company executes against "high-value" commercial and pipeline opportunities that he believes are not yet adequately reflected in the valuation. Cerus's blood pathogen-reduction technology has demonstrated commercial momentum over the past 12 months, and the company's billion-dollar-plus addressable market opportunities are only "marginally appreciated," Blackman tells investors in a research note.
News For CERS From the Last 2 Days
There are no results for your query CERS